{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-060031","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.006427+00:00","generated_at":"2026-06-18T12:57:27.413821+00:00","sec_items":["5.03","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Agios Pharmaceuticals amends bylaws to update proxy rules and meeting procedures","bullets":["Revised procedural mechanics for stockholder nominations under universal proxy rules.","Requires additional background info and representations from proposing stockholders.","Clarifies that failure to comply with Rule 14a-19 may result in disregarding nominations.","Eliminates requirement to make stockholder list available during meeting.","Adds emergency provisions limiting officer/director liability to willful misconduct."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-060031","json":"https://secwatch.observer/filing/0001193125-23-060031.json","markdown":"https://secwatch.observer/filing/0001193125-23-060031.md","text":"https://secwatch.observer/filing/0001193125-23-060031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/0001193125-23-060031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/d638020d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T12:57:27.413821+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"84048208422bacb7b7a07271fc69cb6a41ed8477","claim":"AGIOS PHARMACEUTICALS, INC.: Amended and restated the bylaws to update procedural mechanics and disclosure requirements for stockholder nominations and proposals, among other changes (effective 2023-03-02).","evidence_excerpt":"On March 2, 2023, the Board of Directors (the “Board”) of Agios Pharmaceuticals, Inc. (the “Company”) approved an amendment and restatement of the Company’s Second Amended and Restated By-Laws (as so amended and restated, the “Third Amended and Restated By-Laws”), effective immediately.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523060031/0001193125-23-060031-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-03-02"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}